Venous thromboembolism (VTE) is a chronic disease with a 30% ten‐year recurrence rate.
The highest incidence of recurrence is in the first 6 months. Active cancer significantly …

Both the clinical aspects of the first VTE event and individual characteristics (such as
associated diseases, inherited or acquired thrombophilic conditions, altered D-dimer results …

Patients who have a first episode of venous thromboembolism (VTE) have an elevated risk
of a recurrent episode, and this necessitates secondary prophylaxis. Anticoagulant therapy …

Venous thromboembolism is a major health problem, with an incidence that exceeds 1 per
1000. Over 200,000 new cases occur in the United States annually. Of these, 30% of …

Introduction Venous thromboembolism (VTE) carries a considerable risk of recurrence and
anticoagulants should be administered for a minimum of three months. Since little is known …

The aim of this review was to discuss the epidemiology, risk factors and sequelae of venous
thromboembolism (VTE). VTE has an incidence of 1–2 per 1000 people annually. The risk of …

Initial treatment for venous thromboembolism (VTE) includes the acute and intermediate
phases, usually lasting for 3 months. The choice to extend therapy beyond the initial 3 …

It takes about 3 months to complete “active treatment” of venous thromboembolism (VTE),
with further treatment serving to prevent new episodes of thrombosis (“pure secondary …

To optimize patient outcomes with anticoagulation for venous thromboembolism (VTE), it is
essential to assess patients for their recurrence risk. In this article, I will review the impact of …

The US-wide prevalence of venous thromboembolism (VTE) is unclear, with reported VTE
incidence estimates varying widely. This retrospective analysis of healthcare claims data …